Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2038-03-01
Target enrollment:
Participant gender:
Summary
This is a 2x2 factorial randomized, multicenter, international, open phase III trial.
The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on
overall survival (OS) (main endpoint) for patients with castrate-resistant prostate cancer
starting first line treatment for CRPC